09:00 - 09:50 Registration

09:50 - 10:00 Welcome

10:00 - 10:30 Panel 1: Tyrosine Kinase Inhibitors & Other Novel Mechanisms for the Treatment of Neovascular AMD: Is There Unmet Need?

10:30 - 11:00 Panel 2: The Impact of Extended Duration with Injections on Novel Drug Delivery Approaches for Neovascular AMD

11:00 - 11:30 Networking Break

11:30 - 12:00 Panel 3: Drugs versus non pharmacologic therapies for Slowing Myopia Progression

12:00 - 12:30 Panel 4: When will AI Guided Therapy for Retinal Disease Evolve from Interesting to Essential?

12:30 - 13:00 Panel 5: Surgery & Robotics

13:00 - 13:50 Networking Lunch

13:50 - 15:20 Company Presentations 1

15:20 - 15:30 Investment Perspective

15:30 - 16:00 Panel 6: The Retina Business: Do the Few Wins Justify the Many Losses?

16:00 - 16:30 Panel 7: A View from the Top - Senior Industry Leaders Discuss the Retina Space

16:30 - 16:50 Networking Break

16:50 - 18:30 Company Presentations 2

18:30 - 19:00 Panel 8: Gene & Cell Therapy Outlook for Back of the Eye Diseases: Is this Really a Business?

19:00 - 19:30 Panel 9: GA & Other Dry AMD Therapies: What Lies Ahead in Europe & Beyond?

19:30 - 19:40 Summary

19:40 - 19:45 Concluding Remarks

19:45 - 21:00 Reception 

Please contact the organizer for further information.